Sökning: onr:"swepub:oai:DiVA.org:liu-120358" >
Pharmacokinetics an...
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study
-
- Brodin, Ola (författare)
- Karolinska Institutet
-
- Eksborg, Staffan (författare)
- Karolinska Institutet
-
- Wallenberg, Marita (författare)
- Karolinska Institutet
-
visa fler...
-
- Asker-Hagelberg, Charlotte (författare)
- Medical Prod Agency, Sweden; Karolinska Institute, Sweden
-
- Larsen, Erik H. (författare)
- Technical University of Denmark, Denmark
-
- Mohlkert, Dag (författare)
- Karolinska University Hospital Sodersjukhuset, Sweden
-
- Lenneby-Helleday, Clara (författare)
- Karolinska Institute, Sweden
-
- Jacobsson, Hans (författare)
- Karolinska Institutet
-
- Linder, Stig (författare)
- Karolinska Institutet,Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten,Karolinska Institute, Sweden
-
- Misra, Sougat (författare)
- Karolinska Institutet
-
- Bjornstedt, Mikael (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2015-06-19
- 2015
- Engelska.
-
Ingår i: Nutrients. - : MDPI. - 2072-6643. ; 7:6, s. 4978-4994
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
https://www.mdpi.com...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Sodium selenite at high dose exerts antitumor effects and increases efficacy of cytostatic drugs in multiple preclinical malignancy models. We assessed the safety and efficacy of intravenous administered sodium selenite in cancer patients refractory to cytostatic drugs in a phase I trial. Patients received first line of chemotherapy following selenite treatment to investigate altered sensitivity to these drugs and preliminary assessment of any clinical benefits. Materials and Methods: Thirty-four patients with different therapy resistant tumors received iv sodium selenite daily for consecutive five days either for two weeks or four weeks. Each cohort consisted of at least three patients who received the same daily dose of selenite throughout the whole treatment. If 0/3 patients had dose-limiting toxicities (DLTs), the study proceeded to the next dose-level. If 2/3 had DLT, the dose was considered too high and if 1/3 had DLT, three more patients were included. Dose-escalation continued until the maximum tolerated dose (MTD) was reached. MTD was defined as the highest dose-level on which 0/3 or 1/6 patients experienced DLT. The primary endpoint was safety, dose-limiting toxic effects and the MTD of sodium selenite. The secondary endpoint was primary response evaluation. Results and Conclusion: MTD was defined as 10.2 mg/m(2), with a calculated median plasma half-life of 18.25 h. The maximum plasma concentration of selenium from a single dose of selenite increased in a nonlinear pattern. The most common adverse events were fatigue, nausea, and cramps in fingers and legs. DLTs were acute, of short duration and reversible. Biomarkers for organ functions indicated no major systemic toxicity. In conclusion, sodium selenite is safe and tolerable when administered up to 10.2 mg/m(2) under current protocol. Further development of the study is underway to determine if prolonged infusions might be a more effective treatment strategy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- sodium selenite; carcinoma; pharmacokinetics; maximum tolerated dose
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Brodin, Ola
-
Eksborg, Staffan
-
Wallenberg, Mari ...
-
Asker-Hagelberg, ...
-
Larsen, Erik H.
-
Mohlkert, Dag
-
visa fler...
-
Lenneby-Helleday ...
-
Jacobsson, Hans
-
Linder, Stig
-
Misra, Sougat
-
Bjornstedt, Mika ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Nutrients
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet